Affymax Gets A Gift From Investors: Time
This article was originally published in The Pink Sheet Daily
Executive Summary
It’s not usually the case in biotech, but investors are showing patience for Affymax as it ramps up the launch of its long-acting erythropoiesis stimulating agent Omontys. The drug has yielded nominal sales since its launch in May but Affymax’s stock is up 25% since the drug was approved March 27.